Cargando…

Neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: A SEER based survival analysis

To evaluate the prognostic effect of neoadjuvant chemotherapy (NACT) in advanced epithelial ovarian cancer (EOC) patients with different histological subtype. Stage III/IV EOC patients diagnosed between 2010 and 2018 were identified from the surveillance, epidemiology, and end results database (SEER...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yuexi, Ni, Meng, Huang, Fanfan, Gu, Qiuying, Xiao, Yao, Du, Xinyue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875958/
https://www.ncbi.nlm.nih.gov/pubmed/36705377
http://dx.doi.org/10.1097/MD.0000000000032774
_version_ 1784878061746913280
author Liu, Yuexi
Ni, Meng
Huang, Fanfan
Gu, Qiuying
Xiao, Yao
Du, Xinyue
author_facet Liu, Yuexi
Ni, Meng
Huang, Fanfan
Gu, Qiuying
Xiao, Yao
Du, Xinyue
author_sort Liu, Yuexi
collection PubMed
description To evaluate the prognostic effect of neoadjuvant chemotherapy (NACT) in advanced epithelial ovarian cancer (EOC) patients with different histological subtype. Stage III/IV EOC patients diagnosed between 2010 and 2018 were identified from the surveillance, epidemiology, and end results database (SEER) database and stratified by histological subtype. Kaplan–Meier analysis was used for the assessment of overall survival (OS) cause-specific survival (CSS) before and after matching for baseline characteristics between NACT and primary debulking surgery (PDS) groups. Cox proportional risk model was conducted to identify independent prognostic factors. A total of 13,582 patients were included in the analysis. Of them, 9505 (74.50%) received PDS and 3253 (25.50%) received NACT. Overall, an inferior OS and CSS was observed among patients with high-grade serous carcinoma (HGSC) receiving NACT, while NACT served as a protective factor in clear cell carcinoma and carcinosarcoma in both original cohorts and adjusted cohorts. For other histo-subtypes, PDS showed survival benefit over NACT in certain cohorts of models. Prognostic effect of NACT in advanced EOC differed from pathological subtypes. Although it served as a risk factor for HGSC, patients with less common subtypes may benefit from NACT.
format Online
Article
Text
id pubmed-9875958
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-98759582023-01-27 Neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: A SEER based survival analysis Liu, Yuexi Ni, Meng Huang, Fanfan Gu, Qiuying Xiao, Yao Du, Xinyue Medicine (Baltimore) 5600 To evaluate the prognostic effect of neoadjuvant chemotherapy (NACT) in advanced epithelial ovarian cancer (EOC) patients with different histological subtype. Stage III/IV EOC patients diagnosed between 2010 and 2018 were identified from the surveillance, epidemiology, and end results database (SEER) database and stratified by histological subtype. Kaplan–Meier analysis was used for the assessment of overall survival (OS) cause-specific survival (CSS) before and after matching for baseline characteristics between NACT and primary debulking surgery (PDS) groups. Cox proportional risk model was conducted to identify independent prognostic factors. A total of 13,582 patients were included in the analysis. Of them, 9505 (74.50%) received PDS and 3253 (25.50%) received NACT. Overall, an inferior OS and CSS was observed among patients with high-grade serous carcinoma (HGSC) receiving NACT, while NACT served as a protective factor in clear cell carcinoma and carcinosarcoma in both original cohorts and adjusted cohorts. For other histo-subtypes, PDS showed survival benefit over NACT in certain cohorts of models. Prognostic effect of NACT in advanced EOC differed from pathological subtypes. Although it served as a risk factor for HGSC, patients with less common subtypes may benefit from NACT. Lippincott Williams & Wilkins 2023-01-27 /pmc/articles/PMC9875958/ /pubmed/36705377 http://dx.doi.org/10.1097/MD.0000000000032774 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 5600
Liu, Yuexi
Ni, Meng
Huang, Fanfan
Gu, Qiuying
Xiao, Yao
Du, Xinyue
Neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: A SEER based survival analysis
title Neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: A SEER based survival analysis
title_full Neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: A SEER based survival analysis
title_fullStr Neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: A SEER based survival analysis
title_full_unstemmed Neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: A SEER based survival analysis
title_short Neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: A SEER based survival analysis
title_sort neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: a seer based survival analysis
topic 5600
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875958/
https://www.ncbi.nlm.nih.gov/pubmed/36705377
http://dx.doi.org/10.1097/MD.0000000000032774
work_keys_str_mv AT liuyuexi neoadjuvantchemotherapyinadvancedepithelialovariancancerbyhistologyaseerbasedsurvivalanalysis
AT nimeng neoadjuvantchemotherapyinadvancedepithelialovariancancerbyhistologyaseerbasedsurvivalanalysis
AT huangfanfan neoadjuvantchemotherapyinadvancedepithelialovariancancerbyhistologyaseerbasedsurvivalanalysis
AT guqiuying neoadjuvantchemotherapyinadvancedepithelialovariancancerbyhistologyaseerbasedsurvivalanalysis
AT xiaoyao neoadjuvantchemotherapyinadvancedepithelialovariancancerbyhistologyaseerbasedsurvivalanalysis
AT duxinyue neoadjuvantchemotherapyinadvancedepithelialovariancancerbyhistologyaseerbasedsurvivalanalysis